LDL-Lowering Medications That Increase Hepatic Fat
Lomitapide and mipomersen are the two LDL-lowering medications definitively associated with increased hepatic fat accumulation, with lomitapide causing fatty liver as a recognized adverse effect and mipomersen causing hepatic steatosis of concern. 1
Medications With Established Hepatic Fat Accumulation
Lomitapide (MTP Inhibitor)
- Mechanism: Inhibits microsomal triglyceride transfer protein (MTP), blocking assembly and secretion of VLDL and chylomicrons
- LDL-C reduction: 35-50%
- Hepatic effects: Causes fatty liver (GI symptoms and fatty liver explicitly noted) 1
- Approval status: FDA and EMA approved only for homozygous familial hypercholesterolemia 1
- Clinical implication: The drug prevents hepatic lipoprotein secretion, causing triglycerides to accumulate in hepatocytes rather than being exported 2, 3
Mipomersen (ApoB Antisense Oligonucleotide)
- Mechanism: Antisense oligonucleotide that degrades apoB mRNA, preventing synthesis of apoB-containing lipoproteins
- LDL-C reduction: 30-45%
- Hepatic effects: Increases in transaminase levels and hepatic steatosis are of concern 1
- Approval status: US approval only for homozygous familial hypercholesterolemia 1
- Clinical implication: Like lomitapide, blocks lipoprotein assembly and secretion, trapping lipids in the liver
Medications That May Worsen Pre-existing Steatosis
Methotrexate
- While primarily used for non-lipid indications, methotrexate is documented as a cofactor that can accelerate progression in patients with existing hepatic steatosis, particularly in those who are overweight or diabetic 3
- Duration of exposure and cumulative dose are relevant risk factors 3
Tamoxifen
- Listed among drugs that precipitate hepatic steatosis 3, 4
- Can exacerbate steatosis in patients with underlying metabolic risk factors like obesity and metabolic syndrome 4
Medications That Do NOT Increase Hepatic Fat
Statins
- Do not cause hepatic fat accumulation despite lowering LDL-C by increasing hepatic LDL receptor expression 5
- Recent evidence shows no clinically significant difference in statin response between patients with and without hepatic steatosis 6
- Relatively safe in patients with compensated liver disease 7
Ezetimibe
- Inhibits intestinal cholesterol absorption
- No association with hepatic steatosis 8
- Low incidence of side effects 8
PCSK9 Inhibitors
- Powerful LDL-lowering drugs (40-65% reduction)
- No hepatic steatosis reported 1
- Generally well tolerated 8
Bile Acid Sequestrants
- Can worsen hypertriglyceridemia but not specifically associated with hepatic steatosis 9
- Contraindicated in severe hypertriglyceridemia (>1000 mg/dL) 9
Clinical Pitfalls and Monitoring
Key caveat: Drugs that impair hepatic lipoprotein production and secretion (lomitapide, mipomersen) inherently cause hepatic lipid accumulation because they trap lipids in the liver rather than allowing export 5. This is mechanistically distinct from statins, which increase LDL receptor expression without impairing lipoprotein secretion.
Monitoring requirements for lomitapide and mipomersen:
- Baseline and serial liver transaminases (ALT, AST)
- Assessment for hepatic steatosis
- These agents should only be used in severe, refractory cases (homozygous familial hypercholesterolemia) where benefits outweigh risks 1
Drug history importance: Always document use of medications that may contribute to steatosis (amiodarone, valproate, corticosteroids, tamoxifen, methotrexate) when evaluating patients with suspected NAFLD/MASLD 2, 3